{"id":"sodium-deoxycholate","safety":{"commonSideEffects":[{"rate":"very common","effect":"Swelling and edema at injection site"},{"rate":"common","effect":"Bruising"},{"rate":"common","effect":"Pain and tenderness"},{"rate":"common","effect":"Redness and erythema"},{"rate":"5-10","effect":"Numbness or paresthesia"},{"rate":"common","effect":"Nodules or induration"}]},"_chembl":{"chemblId":"CHEMBL514674","moleculeType":"Small molecule","molecularWeight":"428.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sodium deoxycholate works by solubilizing the cell membrane of adipocytes, leading to cell lysis and permanent destruction of fat cells in the treated area. When injected into subcutaneous fat deposits, it causes a localized inflammatory response that results in apoptosis of adipocytes. The destroyed fat is then cleared by the body's natural inflammatory and metabolic processes.","oneSentence":"Sodium deoxycholate is a bile acid that disrupts cell membranes and causes localized adipocyte destruction when injected subcutaneously.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:27.590Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Submental fat reduction (double chin)"},{"name":"Localized adiposity in other body areas"}]},"trialDetails":[{"nctId":"NCT07237425","phase":"PHASE1","title":"Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma","status":"RECRUITING","sponsor":"Glonova Pharma Co., Ltd","startDate":"2025-11-14","conditions":"Lipoma, Submental Fullness","enrollment":56},{"nctId":"NCT04542473","phase":"PHASE2, PHASE3","title":"Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-07-01","conditions":"SEPSIS, MALNUTRITION, CHILD","enrollment":400},{"nctId":"NCT04531878","phase":"PHASE2, PHASE3","title":"BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2023-02-08","conditions":"Hereditary Diseases, Cholestasis, Intrahepatic","enrollment":""},{"nctId":"NCT03201952","phase":"PHASE1","title":"Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-02-01","conditions":"Glucose Intolerance, Gastric Bypass Surgery","enrollment":2},{"nctId":"NCT02159729","phase":"PHASE2","title":"Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2009-02","conditions":"Submental Fat, Healthy","enrollment":205},{"nctId":"NCT03361176","phase":"PHASE4","title":"Kybella With Triamcinolone","status":"COMPLETED","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2018-03-26","conditions":"Adiposity","enrollment":30},{"nctId":"NCT01904058","phase":"PHASE2","title":"Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2013-08","conditions":"PBC, Primary Biliary Cirrhosis","enrollment":66},{"nctId":"NCT03682471","phase":"","title":"Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-02-14","conditions":"Subcutaneous Fat","enrollment":201},{"nctId":"NCT00851747","phase":"NA","title":"A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2009-02","conditions":"Obesity","enrollment":18},{"nctId":"NCT02979210","phase":"NA","title":"Infant Fecal Insult Study","status":"COMPLETED","sponsor":"Kimberly-Clark Corporation","startDate":"2016-11","conditions":"Dermatitis","enrollment":24},{"nctId":"NCT03241563","phase":"PHASE4","title":"Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat","status":"COMPLETED","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2016-04","conditions":"Fat Reduction","enrollment":20},{"nctId":"NCT01462786","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2011-10","conditions":"Healthy","enrollment":5},{"nctId":"NCT00608842","phase":"PHASE2","title":"Phase 2 Study for the Treatment of Superficial Lipomas","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2007-11","conditions":"Lipoma","enrollment":62},{"nctId":"NCT01426373","phase":"PHASE3","title":"Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2011-08","conditions":"Moderate or Severe Submental Fullness","enrollment":165},{"nctId":"NCT00422188","phase":"PHASE1","title":"Deoxycholic Acid Injection for the Treatment of Superficial Lipomas","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2007-01","conditions":"Lipoma","enrollment":16},{"nctId":"NCT00618722","phase":"PHASE1, PHASE2","title":"Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2007-08","conditions":"Moderate or Severe Submental Fullness","enrollment":85},{"nctId":"NCT01305577","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2010-12","conditions":"Moderate or Severe Submental Fullness","enrollment":363},{"nctId":"NCT00618618","phase":"PHASE2","title":"Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2008-04","conditions":"Moderate or Severe Submental Fullness","enrollment":73},{"nctId":"NCT01542034","phase":"PHASE3","title":"Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2012-02","conditions":"Moderate or Severe Submental Fullness","enrollment":506},{"nctId":"NCT01546142","phase":"PHASE3","title":"Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2012-03","conditions":"Moderate or Severe Submental Fullness","enrollment":516},{"nctId":"NCT01032889","phase":"PHASE2","title":"Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2009-12","conditions":"Moderate or Severe Submental Fullness","enrollment":129},{"nctId":"NCT01294644","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2011-01","conditions":"Moderate or Severe Submental Fullness","enrollment":360},{"nctId":"NCT00618709","phase":"PHASE1","title":"Dose-Escalation Safety and Pharmacokinetic Study of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2008-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT01666223","phase":"NA","title":"Effect of Bile Acids on GLP-1 Secretion","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2012-11","conditions":"Type 2 Diabetes, Obesity","enrollment":20},{"nctId":"NCT01632917","phase":"PHASE1","title":"Open-Label Pharmacokinetic Study of Final Formulations of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2012-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT01674946","phase":"PHASE1","title":"Effect of Bile Acids on the Secretion of Satiation Peptides in Humans","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2011-09","conditions":"Echolocation","enrollment":12},{"nctId":"NCT00912301","phase":"PHASE2","title":"Cheno Effect on Transit in Health and IBS-C","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-04","conditions":"Constipation-predominant Irritable Bowel Syndrome","enrollment":36},{"nctId":"NCT01320761","phase":"PHASE1","title":"A Study to Assess Injection Comfort of Two Formulations of ATX-101","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"","conditions":"Healthy","enrollment":24},{"nctId":"NCT01319916","phase":"PHASE1","title":"Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2010-12","conditions":"Healthy","enrollment":10},{"nctId":"NCT00835952","phase":"PHASE1","title":"ATX-101 Abdominoplasty","status":"COMPLETED","sponsor":"Kythera Biopharmaceuticals","startDate":"2008-11","conditions":"Characteristics of Subcutaneous Fat","enrollment":14}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"MYASTHENIA GRAVIS"},{"count":1,"reaction":"POST PROCEDURAL COMPLICATION"},{"count":1,"reaction":"WAIST CIRCUMFERENCE INCREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kybella"],"phase":"marketed","status":"active","brandName":"Sodium Deoxycholate","genericName":"Sodium Deoxycholate","companyName":"Goldman, Butterwick, Fitzpatrick and Groff","companyId":"goldman-butterwick-fitzpatrick-and-groff","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sodium deoxycholate is a bile acid that disrupts cell membranes and causes localized adipocyte destruction when injected subcutaneously. Used for Submental fat reduction (double chin), Localized adiposity in other body areas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}